Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202

Core Insights - Senti Biosciences, Inc. has received an additional $1.0 million from the California Institute of Regenerative Medicine (CIRM) for achieving clinical study enrollment milestones, bringing the total received from an $8 million grant to $7.4 million [1] - The company is developing SENTI-202, a first-in-class Logic Gated off-the-shelf CAR-NK cell therapy aimed at treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML) [1][3] - Preliminary results from the ongoing Phase 1 trial of SENTI-202 indicate it is well-tolerated, with no dose-limiting toxicities reported and a recommended Phase 2 dose identified as 1.5 x 10^9 CAR NK cells [4] Company Overview - Senti Bio is focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, which aims to enhance precision and control in targeting cancer cells while sparing healthy cells [5] - The company's pipeline includes cell therapies engineered with Gene Circuits to address challenging liquid and solid tumor indications, demonstrating preclinical efficacy in both NK and T cells [5] Clinical Development - SENTI-202 is currently in a Phase 1 clinical trial (NCT06325748) and has shown promising preliminary results, with two out of three patients in the recommended Phase 2 dose cohort achieving a composite Complete Remission (cCR) [4] - The trial data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 supports the Logic Gate mechanism of action, with four out of four cCR patients being Measurable Residual Disease Negative (MRD-) [4]